Key Highlights

  • Second quarter 2026 Net Income reached USD 20.1 million, or USD 0.05 per diluted share, compared with a USD 26.6 million net loss in the same quarter of 2025, according to the August 4 report.
  • Revenue for the quarter climbed to USD 55.0 million from USD 0.9 million, and USD 53.1 million of that came from PAPZIMEOS, the company's FDA-approved therapy for recurrent respiratory papillomatosis.
  • Cash, cash equivalents and investments were USD 38.7 million on June 30, 2026, and management expects Cash Flow to break even by the end of 2026.
  • A published quote showed the shares near USD 4.89, down 6.96%, alongside a 1 year EPS change of 129.04%; the snapshot date is unknown, and both figures are unconfirmed.

How PAPZIMEOS Sales Changed the Income Statement

Precigen operates as a biopharmaceutical company, and Precigen (NASDAQ:PGEN) reported its second quarter on August 4, 2026. PAPZIMEOS, an immunotherapy aimed at HPV 6 and HPV 11, holds FDA approval for adults with recurrent respiratory papillomatosis and carries seven years of market exclusivity. More than 500 patients had enrolled in the company's hub by the report date, while others are treated outside it. Six-month net income came to USD 12.1 million, or USD 0.03 per share, against a net loss of USD 80.8 million a year earlier.

Reimbursement Progress, European Review and the Cash Runway

Payer coverage reaches around 315 million lives in the US, and a permanent J-code, J3404, became effective on April 1, 2026, giving providers a dedicated billing code that may ease reimbursement. The European Medicines Agency is assessing a Marketing authorization application filed in November 2025, and a redosing study is currently enrolling. Management expects current cash together with PAPZIMEOS receipts to fund operations until cash flow breaks even by the end of 2026, although research spending should climb during the year. With USD 38.7 million on hand, the cushion against slower uptake is thin, and no specific Revenue guidance was offered.

Why the 129.04% EPS Figure Reflects a Base Effect

The 129.04% one-year EPS change is a published market data figure that could not be matched to a filing here. Moving from a loss to a profit can generate a very large or undefined growth rate, because the starting point is negative or tiny. The basis, GAAP or adjusted, was not stated, so the figure should be treated as unconfirmed. Third quarter results are set for November 4, 2026, so the next filed numbers arrive today, and the market reaction is still ahead. Investors comparing the quarter will also want to see whether operating expenses grew faster than product revenue.

Where Things Stand

Mostly through one approved product. Precigen (NASDAQ:PGEN) moved from a loss to a profit because PAPZIMEOS lifted quarterly revenue from under USD 1 million to USD 55.0 million in a year. That is a real change in the income statement, but it rests on one therapy for a rare disease and a modest cash balance. The 6.96% decline in the screen price shows how quickly sentiment can shift for a small company, and the figure is unconfirmed published market data rather than a verified close. Third quarter figures on November 4, 2026 will show whether the ramp continued, and the pipeline update promised by year end remains outstanding.